research

Recently, we have seen exciting developments in the antibody-drug conjugate (ADC) space, from cloud computing to radioisotopes.

DAR is key to ADC success. Biointron explains how drug-to-antibody ratios shape potency, safety, and outcomes in cancer therapy.

The 15th World Bispecifics Summit in Boston showcased breakthroughs. Biointron shares highlights shaping the future of bispecific antibody therapeutics.

Phage display technology revolutionizes antibody discovery. Biointron applies this platform to identify high-affinity binders and accelerate therapeutic innovation.

Dilution buffers ensure reliable antibody research. Biointron explains their roles in maintaining stability, accuracy, and reproducibility in experimental workflows.

The 12th Immuno-Oncology Summit in Philadelphia spotlighted antibody therapeutics. Biointron shares event highlights driving progress in cancer immunotherapy.

BIX 2024 in Seoul spotlighted biotech and antibody advances. Biointron reports event highlights shaping innovation across discovery, development, and therapeutics.

PEGS Boston 2024 spotlighted protein and antibody engineering advances. Biointron reports event highlights that define the next era of therapeutic innovation.

Antibodies defend health by neutralizing pathogens, aiding phagocytosis, and activating complement. Biointron explains these vital functions in immunity and therapy.

The 4th Fc-Mediated Function Summit in Boston showcased Fc engineering advances. Biointron reports key insights driving next-generation antibody therapeutics.

Antibody-drug conjugates unite precision with potency. Biointron outlines how ADCs combine antibodies with cytotoxic drugs to deliver targeted cancer therapies.

AACR 2024 in San Diego spotlighted breakthroughs in cancer research. Biointron shares highlights on antibody therapeutics, discovery platforms, and translational science.

Fab, F(ab’)2, and Fc fragments expand antibody applications. Biointron explains their structures and how they advance diagnostics, imaging, and therapeutic innovation.

Biointron shares highlights from Biologics 2024 in London, UK—covering advances in antibody discovery, engineering, and partnerships shaping the future of biologics.

Single-chain variable fragments (scFvs) combine small size with strong binding. Biointron highlights their history, uses in diagnostics and therapy, and production expertise.